Why One Fund Just Bet $4 Million on Teleflex Stock Despite a 42% One-Year Drop

1 week ago 6

Jonathan Ponciano, The Motley Fool

Thu, January 29, 2026 astatine 6:14 AM CST 4 min read

New York City-based Eos Management disclosed a caller presumption successful Teleflex (NYSE:TFX) arsenic of December 31, acquiring 30,831 shares successful a transaction valued astatine $3.76 cardinal based connected quarter-end pricing.

According to an SEC filing dated January 27, Eos Management, L.P. reported establishing a caller involvement successful Teleflex, adding 30,831 shares. The quarter-end worth of the presumption besides accrued by $3.76 million, capturing some the acquisition and immoderate terms changes during the period.

This was a caller position, present representing 1.48% of the fund’s 13F reportable assets.

Top holdings aft the filing:

NYSEMKT:SPY: $75.51 cardinal (29.8% of AUM)
NYSE:BRK-B: $16.71 cardinal (6.6% of AUM)
NASDAQ:GOOGL: $13.52 cardinal (5.3% of AUM)
NASDAQ:MSFT: $11.33 cardinal (4.5% of AUM)
NASDAQ:META: $10.71 cardinal (4.2% of AUM)

As of January 27, shares of Teleflex were priced astatine $104.52, down 42.5% implicit the past twelvemonth and vastly underperforming the S&P 500 by 58.53 percent points.

Metric

Value

Revenue (TTM)	$3.19 billion
Net Income (TTM)	($327.97 million)
Dividend Yield	1.29%
Price (as of January 27)	$104.52

Teleflex Incorporated develops and supplies single-use aesculapian devices, including vascular entree catheters, interventional cardiology products, anesthesia and surgical instruments, urology systems, and respiratory attraction products.
The institution generates gross chiefly done the merchantability of proprietary aesculapian devices utilized successful captious care, surgery, interventional procedures, and urology, targeting some acute and non-acute attraction settings globally.
Its main customers are hospitals, healthcare providers, aesculapian instrumentality manufacturers, and the location attraction market.

Teleflex Incorporated is simply a planetary aesculapian exertion institution with a diversified portfolio of single-use devices supporting captious attraction and surgical procedures. The institution leverages its wide merchandise suite and established brands to code indispensable needs successful hospitals and healthcare facilities worldwide.

What stands retired present isn’t conscionable the timing, but the signifier of the bet. Teleflex has been a uncommon laggard wrong a portfolio different anchored by wide marketplace vulnerability and mega-cap quality. Adding a single-name aesculapian instrumentality banal that’s down much than 40% twelvemonth implicit twelvemonth signals a willingness to measurement into operational uncertainty alternatively than fell down scale momentum.

That uncertainty is real. Teleflex precocious narrowed its preliminary full-year 2025 gross maturation outlook to a scope of 9.0% to 10.0% to a scope of 9.1% to 9.6%. The institution besides entered a enactment modulation successful aboriginal January, naming committee subordinate Stuart Randle interim CEO portion it searches for a imperishable replacement. That operation helps explicate wherefore the banal has trailed the S&P 500 by astir 60 percent points.

Still, the determination suggests assurance that the reset is already priced in. Teleflex is simultaneously shrinking to absorption connected higher-acuity infirmary markets pursuing announced divestitures, a strategy absorption says should amended semipermanent maturation and margins. For a money whose largest holdings stay passive vulnerability and durable compounders, this presumption reads little similar a macro telephone and much similar a selective rebound setup.